Please login to the form below

Not currently logged in
Email:
Password:

Daiichi Sankyo licenses clot-busting antibody

New drug TS23 could be more much effective for ischemic stroke
Daiichi Sankyo Logo

Japan's Daiichi Sankyo has boosted its thrombosis pipeline by licensing a novel clot-dissolving agent from US firm Translational Sciences.

The drug candidate - called TS23 - is in phase I trials but has shown "exceptional efficacy and safety in multiple disease models", according to Memphis-based Translational Sciences.

At the moment blood clots causing diseases such as ischemic stroke, heart attack and acute peripheral vascular ischaemia are generally treated with an injection of tissue plasminogen activator (tPA) products such as Genentech/Boehringer Ingelheim's Activase/Actilyse (alteplase), but Translational Sciences believes there is significant room for improvement.

tPA is the only effective, FDA-approved treatment for ischemic stroke, for example, but is associated with significant risks, delays in treatment and is unsuccessful in up to 70% of patients, leading to death and disability.

Meanwhile, anticoagulants such as warfarin and the newer novel oral anticoagulant (NOAC) class can prevent clots from forming but are unable to dissolve them when already present.

Translational Sciences maintains that its antibody bypasses many of the limitations of TPA and has the potential to be a safer, more effective therapy that allows "early treatment, saves lives, reduces disability and lowers healthcare costs.

"TS23 inactivates a2-antiplasmin (a2AP) - a major inhibitor of clot-dissolving enzyme plasmin - and dissolves clots through a unique mechanism that according to the company "avoids the risk of haemorrhage and neurotoxicity associated with TPA therapy.

"The Memphis company has already garnered around $5m in funding via the US government's Small Business Innovation Research (SBIR) programme, and with Daiichi Sankyo on board will now have the financial backing to accelerate the clinical development of TS23.

The Japanese drugmaker is already a major player in the thrombosis market with products such as Eli Lilly-partnered antiplatelet drug Effient (prasugrel) and recently-introduced NOAC Lixiana (edoxaban).

"This agreement … is in line with the Daiichi Sankyo R&D strategy to expand its portfolio in the prevention and treatment of thrombosis," said the company in a statement.

It will pay Translational Sciences unspecified fees, milestones and royalties for exclusive rights to globally develop and commercialise TS23.

Article by
Phil Taylor

15th September 2015

From: Research

Share

Tags

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Spirit

We find the soul in the science, the humanity in the data, harnessing the power of creativity to deliver medical...

Latest intelligence

competitive intelligence
Integrating competitive intelligence into business development, licensing and M&A strategy
The advantages of partnering with a competitive intelligence or knowledge management team...
reaching HCPs during pandemic
Reaching patients and HCPs during the pandemic
COVID-19 has caused unprecedented disruption to drug launches, but some pharma companies avoided costly delays by quickly pivoting to digital channels...
#DemandDiversity: Black history in clinical trials: It's more than just Tuskegee [Infographic]
Take a look at this infographic showing some of the most notorious clinical trials and medical research in history....

Infographics